retatrutide triple agonist glp-1 gip glucagon phase 3 2025 mechanism receptor just had its biggest data year yet Triple Agonism Based Therapies for

The injectable versus oral peptide comparison is also relevant here, because some researchers transitioning from oral semaglutide may have different GLP-1 receptor adaptation profiles than those coming from injectable formulations

Table of Contents Why Retatrutide Can Cause Fatigue Retatrutide causes fatigue primarily through appetite suppression reducing caloric intake, gastrointestinal side effects causing dehydration, and metabolic adaptation with possible central nervous system effects via GLP-1 receptor activation in the brain

Most patients begin to see resultssuch as improved energy, reduced appetite, and weight losswithin a few weeks

(2018) reported that GLP-1 induces either an increase or a decrease of spontaneous firing rate in GLP-1R expressing BNST neurons

[DOI] [PMC free article] [PubMed] [Google Scholar] 99.Wajdlich M., Nowicki M